PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsOrelabrutinib
Orelabrutinib
Orelabrutinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase BTK.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
87 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.963591450
B-cell lymphoma marginal zoneD018442—C88.4—1211115
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large b-cell lymphoma diffuseD016403—C83.3—93—416
B-cell lymphomaD016393——193—416
Mantle-cell lymphomaD020522—C83.1144——8
B-cell chronic lymphocytic leukemiaD015451—C91.1—32—15
Lymphoid leukemiaD007945—C91—22—14
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3131——4
ThrombocytopeniaD013921HP_0001873D69.6131——4
Non-hodgkin lymphomaD008228—C85.9121——3
LeukemiaD007938—C95—11——2
Multiple sclerosisD009103EFO_0003885G35—11——2
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic lupus erythematosusD008180EFO_0002690M3222———3
NeoplasmsD009369—C8021——13
Relapsing-remitting multiple sclerosisD020529EFO_0003929——1———1
RecurrenceD012008———1———1
Waldenstrom macroglobulinemiaD008258—C88.0—1———1
Neoplasm metastasisD009362EFO_0009708——1———1
Follicular lymphomaD008224—C82—1———1
Hodgkin diseaseD006689—C8111———1
Central nervous system neoplasmsD016543———1———1
InfectionsD007239EFO_0000544——1———1
Show 1 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.91————1
Liver diseasesD008107EFO_0001421K70-K771————1
Hepatic insufficiencyD048550——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———————11
Neuromyelitis opticaD009471EFO_0004256G36.0————11
Neoplasms by histologic typeD009370——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOrelabrutinib
INNorelabrutinib
Description
Orelabrutinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase BTK.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1
Identifiers
PDB—
CAS-ID1655504-04-3
RxCUI—
ChEMBL IDCHEMBL4650321
ChEBI ID—
PubChem CID91667513
DrugBankDB16272
UNII IDWJA5UO9E10 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
BTK
BTK
Organism
Homo sapiens
Gene name
BTK
Gene synonyms
AGMX1, ATK, BPK
NCBI Gene ID
Protein name
tyrosine-protein kinase BTK
Protein synonyms
agammaglobulinaemia tyrosine kinase, Agammaglobulinemia tyrosine kinase, ATK, B-cell progenitor kinase, BPK, Bruton agammaglobulinemia tyrosine kinase, Bruton tyrosine kinase, Bruton's tyrosine kinase, dominant-negative kinase-deficient Brutons tyrosine kinase
Uniprot ID
Mouse ortholog
Btk (12229)
tyrosine-protein kinase BTK (Q61365)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 270 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
111 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use